| 24461/34347 | US=90 / Biol/Mol Blagoev B, Kratchmarova I, Olsen JV, Mann M. EGFR signaling networks: temporal dynamics of EGF receptor signaling by quantitative proteomics. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 199-207. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; NUCLEO; SINALIZAR; TRANSDUCAO |
| 24462/34347 | US=90 / Biol/Mol Johnson CG, McIntyre E, Gullick W. EGFR signaling networks: computational and mathematical modeling of the EGF receptor system. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 209-18. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. |
| 24463/34347 | US=90 / Biol/Mol Normanno N, Bianco C, De Luca A, Strizzi L, Gallo M, Mancino M, Salomon DS. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: expression and prognostic significance of the EGFR in solid tumors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 221-34. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; ERBB2; ERBB3; ERBB4; EGF-COMO FATOR DE CRESCIMENTO; CANCER; PROGNOSTICO |
| 24464/34347 | US=90 / Biol/Mol Bennett HL, Brummer T, Timpson P, Patterson KI, Daly RJ. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: signaling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 235-55. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. SRC; RAS; RAF; ERK; PI3-QUINASE; PTEN; EGFR INIBIDORES; LOOPS DE FEEDBACK; C-CBL; ENDOCITOSE |
| 24465/34347 | US=90 / Biol/Mol Box C, Peak J, Rogers S, Eccles S. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR signaling in invasion, angiogenesis and metastasis. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 257-76. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. INVASAO; ADESAO; MOTILIDADE; PROTEOLISE; ANGIOGENESE; LINFANGIOGENESE; METASTASE |
| 24466/34347 | US=90 / Biol/Mol Wikstrand CJ, Bigner DD. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: constitutive activation of truncated EGF receptors in glioblastoma. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 277-92. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. AMPLIFICACAO DO GENE; IMUNOTERAPIA; MUTACAO; NEOPLASIAS DO SISTEMA NERVOSO; TRANSDUCAO DE SINAL |
| 24467/34347 | US=90 / Biol/Mol Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO |
| 24468/34347 | US=90 / Biol/Mol Dannenberg AJ, Subbaramaiah K. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: crosstalk between COX-2 and EGFR: apontential therapeutic opportunity. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 337-51. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CICLOOXIGENASE-2; PROSTAGLANDINAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; CROSSTALK; CANCER |
| 24469/34347 | US=90 / Biol/Mol Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA |
| 24470/34347 | US=90 / Biol/Mol Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2 |
| 24471/34347 | US=98 / Biol/Mol Kerr JFR. A personal history of the development of the apoptosis concept. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 1-11. ISBN 978-084939192-7. HISTORIA CONCEITO DE APOPTOSE; DESENVOLVIMENTO DO CONCEITO DE APOPTOSE; ENCOLHIMENTO; NECROSE; TUMORES MALIGNOS |
| 24472/34347 | US=98 / Biol/Mol Wilson GD. What do the clinical data tell us about the role of apoptosis in sensitivity to cancer therapy?. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 13-39. ISBN 978-084939192-7. |
| 24473/34347 | US=98 / Biol/Mol Brown M. Response of solid tumors to cancer therapy: how relevant is apoptosis. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 41-53. ISBN 978-084939192-7. |
| 24474/34347 | US=98 / Biol/Mol Lockshin RA, Zakeri Z. Historical studies of various forms of cells death. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 55-72. ISBN 978-084939192-7. |
| 24475/34347 | US=98 / Biol/Mol Bredesen DE. Toward a mechanistic taxonomy for programmed cell death pathways. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 73-91. ISBN 978-084939192-7. |
| 24476/34347 | US=98 / Biol/Mol Egger L. Caspase-independent apoptotic cell death. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 93-108. ISBN 978-084939192-7. CASPASE-INDEPENDENTE DE MORTE CELULAR POR APOPTOSE; INIBICAO DA CASPASE; SINTETICOS INIBIDORES DE CASPASES; CASPASE-MORTE CELULAR INDEPENDENTE |
| 24477/34347 | US=98 / Biol/Mol Madden DT. Autophagic cell death in mammalian cells. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 109-26. ISBN 978-084939192-7. MORTE CELULAR; CELULAS DE MAMIFEROS AUTOFAGICA; AUTOFAGIA E CANCER |
| 24478/34347 | US=98 / Biol/Mol Fan Y, Ullman E, Zong WX. The cellular decision between apoptosis and autophagy. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 127-41. ISBN 978-084939192-7. |
| 24479/34347 | US=98 / Biol/Mol Dawson VL, Dawson TM. Parthanatos: PARP - and AIF-dependent programmed cell death. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 143-56. ISBN 978-084939192-7. PARTHANATOS; PARP; FIA; MORTE CELULAR PROGRAMADA; POLYMERASE-1 |
| 24480/34347 | US=98 / Biol/Mol Sperandio S, Belle I. Paraptosis. In: Roninson IB, Brown JM, Bredesen DE. Beyond apoptosis: cellular outcomes of cancer therapy. New York: Informa Helthcare, 2008. p. 157-74. ISBN 978-084939192-7. |